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Abstract
Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in cancer cells through
numerous mutations and epigenetic changes. The recent development of inhibitors targeting different components of
the PI3K pathway may represent a valuable treatment alternative. However, predicting efficacy of these drugs is
challenging, and methods for therapy monitoring are needed. Basal-like breast cancer (BLBC) is an aggressive breast
cancer subtype, frequently associated with PI3K pathway activation. The objectives of this study were to quantify the
PI3K pathway activity in tissue sections from xenografts representing basal-like and luminal-like breast cancer before
and immediately after treatment with PI3K inhibitors, and to identify metabolic biomarkers for treatment response.
Methods: Tumor-bearing animals (n = 8 per treatment group) received MK-2206 (120 mg/kg/day) or BEZ235 (50 mg/
kg/day) for 3 days. Activity in the PI3K/Akt/mammalian target of rapamycin pathway in xenografts and human biopsies
was evaluated using a novel method for semiquantitative assessment of Aktser473 phosphorylation. Metabolic changes
were assessed by ex vivo high-resolution magic angle spinning magnetic resonance spectroscopy.
Results: Using a novel dual near-infrared immunofluorescent imaging method, basal-like xenografts had a 4.5-fold
higher baseline level of pAktser473 than luminal-like xenografts. Following treatment, basal-like xenografts
demonstrated reduced levels of pAktser473 and decreased proliferation. This correlated with metabolic changes, as
both MK-2206 and BEZ235 reduced lactate concentration and increased phosphocholine concentration in the
basal-like tumors. BEZ235 also caused increased glucose and glycerophosphocholine concentrations. No response
to treatment or change in metabolic profile was seen in luminal-like xenografts. Analyzing tumor sections from five
patients with BLBC demonstrated that two of these patients had an elevated pAktser473 level.
Conclusion: The activity of the PI3K pathway can be determined in tissue sections by quantitative imaging using
an antibody towards pAktser473. Long-term treatment with MK-2206 or BEZ235 resulted in significant growth
inhibition in basal-like, but not luminal-like, xenografts. This indicates that PI3K inhibitors may have selective
efficacy in basal-like breast cancer with increased PI3K signaling, and identifies lactate, phosphocholine and
glycerophosphocholine as potential metabolic biomarkers for early therapy monitoring. In human biopsies, variable
pAktser473 levels were observed, suggesting heterogeneous PI3K signaling activity in BLBC.
Introduction
Basal-like breast cancer (BLBC) accounts for approxi-
mately 15-20% of breast cancers, and has the least favor-
able prognosis of all breast cancer subtypes. BLBC often
occurs in women younger than 40 years and is associated
with short time to metastasis and short overall survival
compared with other subtypes of breast cancer [1,2].
Introduction of drugs targeting oncogenic signaling path-
ways may represent a new paradigm in the treatment of
BLBC [1,3]. Basal-like breast cancer frequently exhibits the
triple negative phenotype. In contrast to other breast can-
cer subtypes, these patients currently lack targeted treat-
ment alternatives and would therefore benefit from the
introduction of new, molecularly targeted drugs. However,
introduction of targeted therapy will also depend on the
development of diagnostic approaches to evaluate whether
the relevant target is driving tumor progression.
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For breast cancer, the presence of human epidermal
growth factor receptor 2 (HER2) amplification predicts
possible positive effects of injected neutralizing antibo-
dies [4]. Predicting efficacies of a targeted drug from
DNA sequence variations have proven useful for treat-
ment of lung cancers with epidermal growth factor
receptor inhibitors [5,6]. However, predicting the activity
in the phosphatidylinositol 3-kinase (PI3K)/Akt/ mam-
malian target of rapamycin (mTOR) pathway based on
DNA sequence alterations is complex. The activity in the
pathway seems to depend on a number of alternative
mechanisms, including amplification or activating muta-
tions in PIK3CA, loss of phosphatase and tensin homolog
(PTEN) protein at a DNA, mRNA or protein level, or
activating mutations/amplification in AKT1/AKT2 [7-10].
Owing to the number of different mechanisms that,
directly or indirectly and at different levels, can lead to
elevated PI3K pathway activity, development of methods
that quantitatively report on signaling activity in the
tumor tissue is tempting. Conventional immunohisto-
chemistry using antibodies for active, phosphorylated Akt
has been suggested, but this approach is limited by its
low linear range and by the difficulty in introducing a
second stain for normalizing purposes.
To accelerate the introduction of targeted drugs into
clinical practice, identification of molecular biomarkers
for early monitoring of response to therapy and develop-
ment of resistance is required [11,12]. Assessment of
tumor metabolism using magnetic resonance spectro-
scopy (MRS) is a promising approach for biomarker dis-
covery, since the metabolic characteristics of cancer are
inherently different from normal tissue and since onco-
genic signaling regulates energy metabolism in cancer
cells [13,14]. Identification of metabolic biomarkers is
therefore an important step in the introduction of
rational, personalized treatment of BLBC patients with
drugs targeting oncogenic signaling.
Inhibitors targeting components of the PI3K pathway
are a promising new class of drugs currently evaluated
in various cancers. They are of particular interest in
BLBC, because abnormal activity in the PI3K/Akt/
mTOR signaling axis has been described both in precli-
nical models and in clinical cohorts in this breast cancer
subtype [8,15-17]. Metabolic effects of PI3K inhibition
in cancer have been studied in vitro and in vivo [12].
However, data on metabolic effects in basal-like breast
cancer are lacking, and the effect of PI3K inhibition on
choline metabolism in breast cancer has not yet been
studied in in vivo models. Different subtypes of cancer
have distinct metabolic profiles and the flux through
metabolic pathways is in part governed by the oncogenic
signaling.
We have therefore studied PI3K/mTOR/Akt pathway
activity in basal-like and luminal-like breast cancer
xenografts, and the effect of the pan-Akt inhibitor MK-
2206 and the dual PI3K/mTOR inhibitor BEZ235 in
these models in vivo. The response to treatment was
evaluated both with respect to tumor volume, cellular
proliferation and blockade of PI3K signaling. Metabolic
changes in the tumor tissue were examined by ex vivo
high-resolution magic angle spinning (HR MAS) MRS.
The objectives of the study were to use a novel immuno-
fluorescence imaging method to quantify the level of
pAktser473 in tumor tissue sections, to determine whether
inhibition of the PI3K signaling pathway caused anti-
tumor effects in the basal-like xenograft model, and to




The MAS98.12 (basal-like) and MAS98.06 (luminal-like)
breast cancer xenograft models have previously been
established by orthotopic implantation of biopsy tissues
from primary mammary carcinomas in severe combined
immunodeficiency mice [18].
For both xenograft models, animals were randomized
into the following treatment groups (n = 8 per group):
vehicle control (0.2 ml/day), MK-2206 (120 mg/kg/day)
and BEZ235 (50 mg/kg/day). MK-2206 (Selleck Chemicals,
Houston, TX, USA) was dissolved in dimethyl sulfoxide
and diluted in 30% Captisol® (CyDex Pharmaceuticals,
Inc., Lenexa, KS, USA) to a final concentration of 15
mg/ml. BEZ235 (Selleck Chemicals) was dissolved in
N-methyl-2-pyrrolidone and diluted in 30% Captisol® to a
final concentration of 6.5 mg/ml. Vehicle control solution
consisted of dimethyl sulfoxide, N-methyl-2-pyrrolidone
and 30% Captisol® (1:1:2). These dose levels have pre-
viously shown efficacy in murine xenograft models [19,20].
The drugs were administered by gavage for 3 consecu-
tive days. Tumor volume was measured before and after
treatment using external calipers (volume = πab2 / 6,
where a and b represent the longest diameter and shortest
diameter, respectively). After treatment, tumor tissue was
harvested and preserved for histopathology (4% neutral
buffered formalin) or snap frozen in N2(l) for metabolic
profiling.
An additional batch of mice (n = 5 or 6 per group) was
randomly assigned to treatment as described above when
the tumor diameter reached approximately 5 mm and
was treated with MK-2206 or BEZ235 for up to 26 days.
The tumor volumes were measured regularly with cali-
pers during the treatment period.
All procedures and experiments involving animals
were approved by the National Animal Research
Authority, and were carried out according to the Eur-
opean Convention for the Protection of Vertebrates
used for Scientific Purposes.
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Histopathology
Tumor tissue was fixed in 4% formaldehyde immediately
after isolation from the animal and embedded in paraffin.
Sections were cut at 4 µm and mounted on glass slides.
Immunohistochemical staining for the mitosis marker
phosphohistone H3 (PHH3) was carried out as previously
described [21]. Mitotic activity was counted in PHH3-
stained sections according to Skaland and colleagues
[22], and was reported as the number of positive counts
per 10 fields of view. Necrotic areas were avoided.
For analysis of the activity in the PI3K/Akt pathway, sec-
tions were co-stained with mouse anti-pan-Akt antibody
(#2920; Cell Signaling Technology, Beverly, MA, USA)
and rabbit anti-pAktser473 antibody (#4060; Cell Signaling
Technology). Four different secondary antibodies were
used to image binding of the primary antibodies. For con-
focal microscopy, anti-mouse conjugated with Alexa 488
and anti-rabbit conjugated with Alexa 555 (Invitrogen,
Paisley, UK) were used. For near-infrared (NIR) immuno-
fluorescence imaging, anti-rabbit conjugated with IR-680
dye and anti-mouse conjugated with IR-800 dye (Li-Cor
Biosciences, Lincoln, NE, USA) were used. All secondary
antibodies were added simultaneously in a 1:1 ratio to
allow combined low-resolution quantifications using NIR
fluorescent scanning and high resolution of regions of
interest using confocal microscopy in the visible area of
the light spectra. Negative control sections were prepared
by staining with secondary antibodies only.
Near-infrared immunofluorescence imaging
Stained tissue sections (n = 4 in all treatment groups)
were scanned on an Odyssey Infrared Imaging System
(Li-Cor Biosciences) with a spatial resolution of 21 µm.
The samples were scanned simultaneously to enable
quantitative image analysis. The signals were recorded in
separate channels for concurrent imaging of pAktser473
(700 nm) and total Akt (800 nm) levels. The images were
exported as colorized 32-bit .tiff files and the signal
intensity was quantified using ImageJ (National Institute
of Health, Bethesda, MD, USA). Regions of interest
enveloping the entire tumor area were defined and the
mean signal intensity for each region of interest was
determined. Compensation for autofluorescence and
unspecific antibody binding was performed by subtrac-
tion of the mean signal from adjacent negative control
sections. The signal intensity was compared across treat-
ment groups using the Student’s t test with the threshold
for statistical significance defined as P ≤0.05. Confocal
microscopy was carried out using an Axiovert micro-
scope (Carl Zeiss MicroImaging Inc., Jena, Germany)
with 20× and 63× magnification, and images were cap-
tured and analyzed using Zeiss LSM Meta and Zeiss LSM
Image Examiner (Carl Zeiss MicroImaging Inc.).
Human breast cancer biopsies
To evaluate the feasibility of the NIR immunofluores-
cence imaging method in human tumor tissue, five par-
affin-embedded specimens from patients with BLBC
were retrieved from the Breast Cancer Subtypes research
biobank, NTNU, which has been approved by the Regio-
nal Research Ethics Committee. The tumors were classi-
fied as BLBC using immunohistochemical and in situ
hybridization methods as surrogates for gene expression
profiling. On immunohistochemical stained tissue
microarrays, the tumors were estrogen receptor negative
(249R-16/SP1; Cell Marque, Rocklin, CA, USA) and pro-
gesterone receptor-negative (NCL-PGR 312-CE; Leica
Biosystems, North Ryde, Australia) but were positive for
cytokeratin 5 (Ncl-CK5-L-CE; Leica Biosystems) and/or
epidermal growth factor receptor (K1494/2-18C9; Dako
Denmark/Glostrup, Denmark) developed using
pharmDx™ (Dako, Denmark). The tumors were also
negative for HER2 using chromogenic in situ hybridiza-
tion for the HER2 gene and the chromosome 17 centro-
mere (HER2 CISH pharmDx™; Dako, Denmark) (gene:
chromosome ratio <2.0).
For NIR fluorescence staining, the clinical samples
were stained and imaged according to the protocol
described above. The primary antibodies were omitted
as a negative control of the immunostaining. The sec-
tions were stained, imaged and processed simultaneously
and quantifications were performed using the Li-Cor
software. After subtracting the signal intensity for the
negative control in each channel, the mean intensity for
the anti-pAktser473 labeling was divided by the signal
intensity for the total Akt labeling. One of the biopsies
contained both normal and cancerous tissue and
allowed comparison of the pAktser473 signal in the differ-
ent parts of the section.
Western blotting
Snap-frozen tumor samples were thawed and immediately
lysed in a lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 1 mM ethylenediamine tetraacetic acid, 1% NP-40,
0.25% Triton X-100) with phosphatase inhibitor (Com-
plete Lysis-M; Roche Diagnostics, Indianapolis, IN, USA)
and a combination of phosphatase inhibitor cocktails 2
and 3 (Sigma-Aldrich, St Louis, MO, USA). The protein
concentration was determined in clear cell lysates and
equal amounts of total protein (50 μg) were separated by
SDS-PAGE. After immunoblotting, the membranes were
developed using a mixture of the anti-pAktser473 and pan-
Akt antibodies and were imaged after labeling with NIR
fluorescent secondary antibodies. PTEN levels in the
tumor lysates were detected using a C-terminal PTEN
antibody (#18-0256; Invitrogen) and pAktthr308 detected by
a monoclonal rabbit antibody (#2965; Cell Signaling
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Technology). The amount of b-actin (#ab6276; Abcam,
Cambridge, UK) in the lysates was used as control of
equal protein loading. Binding of the respective primary
antibodies was detected using secondary antibodies labeled
with NIR fluorescent dyes. The images from the Odyssey
Infrared Imaging System were processed using the Li-Cor
software and mounted using Canvas (ACD Systems Inter-
national Inc, Seattle, WA, USA).
Metabolic profiling using high-resolution magic angle
spinning magnetic resonance spectroscopy
Frozen xenograft tissue was cut to fit into 30 µl disposable
inserts (Bruker BioSpin, Ettlingen, Germany) filled with 3
µl PBS/D2O buffer containing trimethylsilylpropanoic acid
as a chemical shift reference. The average weight of the
tissue samples was 12 ± 3 mg. Samples were analyzed
using a Bruker AVANCE DRX-600 spectrometer equipped
with a 1H/13C HR MAS probe (Bruker BioSpin). Samples
were spun at 5 kHz and the instrument temperature was
maintained at 4°C for all experiments. A single-pulse
experiment (zgpr; Bruker) was performed for all samples.
The water resonance was suppressed using a presaturation
delay of 3 seconds and an acquisition time of 3.40 seconds.
A sweep width of 16 ppm was used for signal collection.
Thirty-two free induction decays were acquired into 64k
points.
A creatine reference solution (9.05 μmol/g) was ana-
lyzed under identical conditions for use as an external
calibration standard. Post-processing of spectra included
0.3 Hz exponential line broadening and baseline correc-
tion using a fifth-order function.
Chemical shifts were calibrated to the trimethylsilylpro-
panoic acid at 0.0 ppm. Assignment of metabolite peaks
was performed with reference to previously published
data [23]. The peak area of each metabolite was calcu-
lated by polynomial regression (PeakFit v 4.12; Systat
Software Inc, Chicago, IL, USA). The correlation coeffi-
cient of the fit (r2) for all spectra was ≥0.95. Concentra-
tion of each metabolite was calculated with reference to
the recorded sample weight and the peak area of the
creatine reference solution. Metabolite concentrations
were compared across treatment groups using Student’s
t test with the threshold for statistical significance
defined as P ≤0.05.
Results
Determining PI3K pathway activity in basal-like and
luminal-like xenografts
Previous gene expression analysis has suggested
increased PI3K signaling in the MAS98.12 xenograft
model, which represents basal-like breast cancer [18].
Another model established in the same study represents
estrogen receptor-positive luminal-like breast cancer,
and was not associated with high PI3K signaling activity.
We therefore hypothesized that a difference in PI3K/
Akt/mTOR pathway activity in these two xenograft
models could be detected by immunostaining.
PI3K indirectly activates the downstream kinase Akt,
which is activated by phosphorylation of two sites:
threonine 308 and serine 473. To determine the activity
of this pathway we therefore stained for the phosphory-
lated activated form of Akt (pAktser473). NIR immuno-
fluorescence imaging demonstrated a clearly increased
pAktser473 signal in the basal-like xenografts (Figure 1A).
The increase was due to a specific activation of Akt
since no differences in the total Akt level between the
two cancer types could be observed. Omitting the pri-
mary antibodies against active and total Akt demon-
strated a very low background staining in the 700 nm
channel for the rabbit IgG detecting pAktser473. In the
800 nm channel used to image total Akt, however,
regional staining was observed even in the absence of
the primary antibody. The unspecific staining was con-
fined to areas containing stromal tissue and to necrotic
areas. This nonspecific binding of the secondary anti-
body most probably represents binding of the secondary
anti-mouse IgG antibody to host immunoglobulins.
Despite the nonspecific binding, we could still observe a
specific signal of total Akt that is considered to reflect
all Akt isoforms in the tumor cells. By quantification of
the NIR immunofluorescence images, we corrected for
nonspecific binding by subtracting the signal intensity in
an adjacent tissue section. Comparing the signal inten-
sity of stained sections from the xenografts we found a
nearly fivefold higher pAktser473 signal in basal-like
tumors compared with luminal-like tumors (Figure 1B).
The total Akt signal was higher than the negative con-
trol in all examined specimens (P <0.00003) but we
found no difference in total Akt between the two tumor
types (Figure 1B).
To confirm the findings from immunofluorescence ima-
ging, the level of pAktser473 was determined in tumor
lysates by western blotting (Figure 1C). The anti-pAktser473
antibody generated a band at the expected location. This
band was eightfold increased in extracts from basal-like
tumors compared with luminal-like tumors. For the quan-
tifications, the pAktser473 signal was normalized to the
total Akt levels in the respective samples. The immunoglo-
bulin heavy chain from the xenograft host gave an
approximately 50 kDa band that migrated slightly faster
than Akt, and could be detected in the absence of the pri-
mary total Akt antibody. However, the total Akt signal
could only be detected after incubation with the primary
antibody. Activation of Akt involves also the phosphoryla-
tion of the threonine 308 residue. However, even though
an elevated level of pAktthr308 could be detected in extracts
of the basal-like tumors by immunoblotting (Figure 1D),
we could not obtain acceptable signal-to-noise ratios using
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Figure 1 pAktser473 is elevated and phosphatase and tensin homolog lost in basal-like but not luminal-like xenografts. (A) Immunostaining
of luminal-like (LL; top) and basal-like (BL; bottom) xenograft tumor sections from the vehicle control group, stained with anti-pAktser473 (red) and anti-
pan-Akt (green) antibodies, and secondary antibodies conjugated with near-infrared (NIR) fluorescent dyes (red channel, pAktser473; green channel,
pan-Akt). Negative control sections were stained with secondary antibodies alone (left two images in the panels). Tumors were isolated 3 days after
the start of the treatment and 5 hours after the last supplementation of the respective drugs. All scale bars = 1 mm. (B) Quantification data from NIR
immunofluorescence imaging (n = 4). The signal intensity of the total Akt immunostaining is similar in BL and LL xenografts, whereas the signal for
pAkt ser473 is approximately fivefold higher in BL compared with LL xenografts. **P <0.0005. (C) Immunoblot analysis of the level of pAktser473, total Akt
and phosphatase and tensin homolog (PTEN) in lysates from two different BL and LL cancers. Level of b-actin included as a loading control. Numbers
above the images and the lanes in the immunoblot refer to the individual tumor-bearing mouse. (D) Higher phosphatidylinositol 3-kinase (PI3K)
signaling activity in BL xenografts was also confirmed by immunoblot analysis of pAktthr308 levels.
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the pAktthr308 antibody in immunofluorescence images.
Previous gene expression analysis has identified a clear
reduction in mRNA levels of the tumor suppressor PTEN
in the basal-like xenograft [18]. Accordingly, the level of
PTEN protein was more than six times lower in the
extracts from basal-like xenografts compared with lumi-
nal-like xenografts (Figure 1C).
We then assayed the effect of the PI3K pathway inhibi-
tors BEZ253 and MK-2206 on the pAktser473 levels (Fig-
ure 2A). Immunostaining of sections from the basal-like
xenografts demonstrated sixfold and twofold reductions
in the pAktser473 level in response to treatment with
BEZ253 and MK-2206, respectively (P <0.01) (Figure 2B).
Although BEZ235 had a strong inhibitory effect on the
pAktser473 level in basal-like xenografts, the observed sig-
nal was still significantly higher than in the negative con-
trol (P = 0.01). In the luminal-like xenografts, no
significant reduction of the low level of pAktser473 in
response to any of the two compounds was observed. To
verify that the differences in staining intensity were due
to reduced pAktser473 levels, we analyzed lysates from the
frozen cancer samples by immunoblotting (Figure 2C). In
accordance with the immunostaining, we found a clear
reduction in the pAktser473 level in the lysates from basal-
like tumors in response to both MK-2206 and BEZ235.
No changes in total Akt level were observed after any
treatment.
The use of NIR dyes conjugated to the respective sec-
ondary antibodies allowed co-staining with secondary anti-
bodies that can be imaged by conventional confocal
microscopy. Based on the finding that basal-like xenografts
had a significantly elevated pAktser473 level, the subcellular
localization of pAktser473 was examined by confocal micro-
scopy. In basal-like control tumors, a clearly elevated
plasma membrane-enriched pAktser473 signal was
observed. In response to treatment with MK-2206 and
BEZ235, this signal was clearly reduced (Figure 3). As for
the NIR scanning, we observed an unspecific signal in the
800 nm channel for total Akt that probably represents
binding of anti-mouse IgG secondary antibodies to xeno-
graft host immunoglobulins. This unspecific staining
seemed to be limited to extracellular space consistent with
binding of the secondary antibody to host immunoglobu-
lins. However, there was still a detectable specific intracel-
lular signal for total Akt that was enriched in the plasma
membrane in tumors from untreated animals but more
diffuse in the cytosol after treatment. No nuclear staining
of pAktser473 was observed.
In summary, immunostaining of tumor sections
detected either by NIR scanning or confocal microscopy
as well as immunoblotting of lysates from the same
tumors demonstrates that the level of pAktser473 was ele-
vated in the basal-like xenografts compared with the lumi-
nal-like xenografts. Further, we observed a marked
reduction of pAktser473 levels in response to treatments
targeting the PI3K pathway in the basal-like xenograft
model. In the luminal-like cancer model, the level of pAkt-
ser473 was low in the vehicle-treated control animals and
we could not observe any reduction of this low level in
response to treatment.
PI3K pathway activity in human basal-like breast cancer
NIR scanning and confocal microscopy demonstrated an
elevated level of pAktser473 in the MAS98.12 basal-like
xenograft model. To see whether this animal model is
representative for BLBC, we determined the level of
pAktser473 in tumor sections from five human BLBC
biopsies. As expected, we observed that there was very
little unspecific signal in the absence of the primary anti-
bodies (Figure 4A). This highly reduced background in
the clinical BLBC samples is very probably due to the
absence of mouse immunoglobulins that can bind the
secondary antibodies and give an unspecific signal. The
sample that demonstrated strongest pAktser473 signal
contained both normal and cancerous tissue. Impor-
tantly, the pAktser473 signal was found elevated only in
the part of the sample that contained tumor cells.
The pAktser473 signal was then quantified relative to
total Akt. The cancerous tissue in the heterogeneous sec-
tion had an approximately five times higher pAktser473
level compared with the normal tissue in the same sec-
tion (Figure 4B). Another of the samples also displayed
an elevated pAktser473 signal, but this sample also con-
tained more total Akt. This sample from the pathologist
was classified as homogeneous cancerous tissue and was
found to have an approximately threefold higher pAkt-
ser473 signal after normalization against the total Akt
staining. The last three BLBC samples did not show ele-
vated pAktser473 levels. In line with the basal-like xeno-
graft model, we found that pAktser473 was mainly located
to the plasma membrane in the cancerous tissue of the
section that demonstrated a fivefold increase in pAkt.
None of the other samples demonstrated a pAkt signal
that could be detected using the confocal microscope.
Collectively, these results suggests that the established
NIR-based immunofluorescence protocol for semiquanti-
tative dual imaging of pAktser473 and total Akt is well sui-
ted for analysis of clinical samples. Moreover, the five
clinical samples analyzed confirm the variability in PI3K
signaling observed in other studies of BLBC [8,24].
In vivo anti-tumor effects of PI3K inhibitors in basal-like
and luminal-like xenografts
There was a marked difference in response to PI3K inhibi-
tion between the two xenograft models. The volume of
basal-like xenografts treated with MK-2206 or BEZ235 was
reduced 3 days after initiation of treatment (-11 ± 26% and
-12 ± 17%, respectively, compared with the pretreatment
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volume). In contrast, the volume of vehicle-treated basal-
like xenografts increased significantly (28 ± 30% from the
pretreatment volume, P = 0.002) in the same timespan. In
luminal-like xenografts, no significant change in tumor
volume was observed either in controls or treated animals.
The absence of volume change in luminal-like xenografts
over the 3-day treatment course could, however, reflect the
slow growth rate of this model.
In the vehicle-treated controls, mitotic activity (measured
by PHH3 staining) was higher in basal-like xenografts than
in luminal-like xenografts (41 ± 12 vs. 26 ± 4 counts/10
fields of view, P <0.01). This increased activity confirms
Figure 2 Three-day treatment of drugs targeting phosphatidylinositol 3-kinase pathway reduces active Akt level in basal-like
xenografts. (A) Immunostaining of tissue sections from basal-like (BL; left) and luminal-like (LL; right) xenografts given vehicle control (upper
panel), MK-2206 (middle panel) or BEZ253 (lower panel). pAktser473 (red) and total Akt (green) are stained as in Figure 1. All scale bars = 1 mm.
(B) Quantification data from near-infrared (NIR) immunofluorescence imaging (n = 4). The signal intensity was significantly reduced after
treatment with MK-2206 and BEZ235 in BL but not in LL xenografts. *P <0.05, **P <0.0005. (C) Immunoblot analysis of tumor lysates for the level
of pAktser473 (upper panel) and b-actin loading control (lower panel). Lysates were prepared from tumors harvested 3 to 6 hours after the last
administration of MK-2206 and BEZ235.
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the faster growth rate of the basal-like xenografts. In the
basal-like xenografts, PI3K inhibition significantly (P
<0.005) reduced the mitotic activity (21 ± 6 and 11 ± 3
counts/10 fields of view) for MK-2206 and BEZ235,
respectively) (Figure 5A). The reduction in mitotic activity
in the BEZ235 group was stronger than in the MK-2206
group (P <0.005). In the luminal-like xenografts, BEZ235
treatment did not reduce the mitotic activity (18 ± 10
counts/10 fields of view). In the MK-2206 group, a para-
doxical increase in mitotic activity was observed
(P <0.001). The reduction in pAktser473 in basal-like xeno-
grafts treated with BEZ235 and MK-2206 correlated
strongly with the mitotic rate (Figure 5B).
Long-term treatment with MK-2206 and BEZ235 caused
a significant growth delay in basal-like xenografts (Figure
5C). At the time point where vehicle-treated controls had
to be sacrificed due to their tumor burden (19 days after
start of treatment), the tumor volume of BEZ235-treated
mice was 33% of the controls (P <0.00001). No significant
difference between BEZ235-treated and MK-2206-treated
mice was observed. In the slower-growing luminal-like
xenografts, there was no significant difference between the
treated group and the vehicle control group (P = 0.14)
(Figure 5D).
Identification of metabolic biomarkers for response to
PI3K inhibition
The metabolic profiles from vehicle-treated tumors con-
firmed the differences between basal-like and luminal-
like xenografts observed in previous studies [25,26]. This
model has a characteristic metabolic profile, with a gly-
cerophosphocholine (GPC):phosphocholine (PCho) ratio
>1 and significantly higher glycine concentration than
the luminal-like xenograft. The metabolite concentra-
tions from all treatment groups are presented in Table
S1 in Additional file 1.
Treatment-related changes in metabolite concentrations
were seen in basal-like xenografts, but not luminal-like
xenografts (Figure 6). After treatment with MK-2206,
PCho increased by 45% compared with vehicle controls
whereas lactate decreased by 33%. In xenografts treated
with BEZ235, the metabolic response was more pro-
nounced. PCho and GPC concentrations increased two-
fold, and lactate concentrations were reduced by 44%. In
Figure 3 Plasma membrane-associated pAktser473 is lost in response to targeted inhibition of the phosphatidylinositol 3-kinase pathway.
Tumor sections from vehicle control (two upper panels) or MK-2206-treated (lower left panel) or BEZ253-treated (lower right panel) mice were stained
with secondary antibodies alone (negative control; upper left panel) or with anti-pAktser473 (red) and total Akt (green). DNA was visualized by
4’,6-diamidino-2-phenylindole (DAPI) staining. Images were obtained using identical settings in the confocal microscope using a 20× objective.
The sections were first imaged with a near-infrared (NIR) scanner and subsequently imaged by confocal microscopy to detect the fluorescent-labeled
antibodies in the visible light area. Treatment with MK-2206 or BEZ235 causes a marked reduction of pAktser473 levels, and loss of membrane
localization compared with vehicle-treated controls. Numbers above the images refer to the individual tumor bearing mouse. All scale bars = 20 µm.
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Figure 4 pAktser473 is elevated in a subset of clinical samples of basal-like breast cancer. (A) Sections from five clinical samples classified as
basal-like breast cancer were immunostained for total Akt (green, 800 nm) or pAktser473 (red, 700 nm) and scanned using the near-infrared (NIR)
scanner. The sample from Case 129 contains both normal tissue (NT) and cancerous tissue (CT). In Case 72, there was a longitudinal structure in the
section that contained skin and resulted in a structure that is faintly visible in the negative control and also demonstrated elevated signal of both total
Akt and pAktser473. The samples from the last three cases were classified as homogeneous basal-like breast cancer (BLBC). Scale bar = 5 mm.
(B) Quantification of the pAktser473 signal relative to the total Akt signal in the different clinical BLBC samples. For Case 129, the pAktser473 was
quantified both in the NT and in the CT. Quantifications were done in three to five randomly selected circular regions of interest of the tumors and
presented as the mean relative intensity in the different areas with standard deviations. (C) The pAktser473 signal is mainly located to the plasma
membrane of the cancer cells in BLBC. Imaged area is from the area labeled with an arrowhead in (A). Scale bar = 20 μm.
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addition, the glucose concentration was increased nearly
threefold. The magnitude of change in the metabolic bio-
markers was therefore closely associated with the reduc-
tion in pAktser473 level. Example spectra illustrating the
metabolic changes are presented in Figure 7.
Discussion
In this study, the response to two PI3K inhibitors with dif-
ferent molecular targets was evaluated in two different
breast cancer xenograft models. Combined NIR and con-
focal immunofluorescence imaging was used to evaluate
the baseline level of PI3K signaling in the tumors and to
determine the pharmacodynamic effects of drugs targeting
the PI3K pathway. Ex vivo HR MAS MRS was used to
identify metabolic biomarkers for response to therapy.
Basal-like xenografts had significantly higher pAktser473
levels at baseline, but the phosphorylation was significantly
reduced after treatment with BEZ235 and MK-2206. This
response was accompanied by early changes in phospholi-
pid and glucose metabolism, reflecting the long-term
tumor growth delay caused by PI3K inhibition in this
model.
The basal-like and luminal-like xenograft models are
established from human primary breast carcinomas
directly transplanted to immunodeficient mice. They
represent breast cancer with poor (basal-like) and good
(luminal-like) prognosis, and have retained the gene
expression profile and morphology from the primary
tumors [18]. Since patient-derived xenografts represent
the cellular heterogeneity of human breast cancer, they are
considered to be of high clinical relevance [27]. Previous
studies have shown that the basal-like xenograft has a
Figure 5 Reduced pAktser473 levels are correlated with tumor growth inhibition and reduced proliferation in basal-like xenografts.
(A) Mitotic activity (phosphohistone H3 (PHH3) counts/10 fields of view) in basal-like and luminal-like xenografts after treatment with MK-2206
and BEZ235. (B) Correlation between pAktser473 signal intensity and mitosis in basal-like xenografts treated with vehicle (open squares), MK-2206
(filled circles) and BEZ235 (open triangles). (C) Tumor volumes (relative to day 0) in basal-like xenografts treated with MK-2206 (filled circles) and
BEZ235 (open triangles), compared with vehicle-treated controls (open squares). (D) Tumor volumes (relative to day 0) in luminal-like xenografts
treated with MK-2206 (filled circles) and BEZ235 (open triangles), compared with vehicle-treated controls (open squares).
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triple-negative phenotype, active angiogenesis and a rapid
growth rate compared with the hormone-sensitive lumi-
nal-like xenograft model [21]. Gene set enrichment analy-
sis has suggested overactivity in the PI3K signaling
pathway [18].
Using a flat-bed NIR fluorescence imager, the levels of
pAktser473 could be assayed with minimal autofluorescence
interference. Subtraction of the signal intensity from tissue
sections representing the background levels has been
shown to allow quantitative measurement of fluorescent
probes with high accuracy [28]. This method allowed
semiquantitative analysis of the signal intensity originating
from the specifically bound antibodies. This was con-
firmed by western blotting of the same tissue specimens.
The NIR imaging method opens for automated, quantita-
tive imaging of PI3K pathway activity in tumor samples.
As for immunostaining in general, this NIR imaging
approach is highly dependent on the quality of the antibo-
dies and we have not yet identified an anti-pAktthr308 anti-
body that can be used for immunostaining.
The resolution of the images (21 μm) was sufficient to
determine relatively fine spatial differences in signaling
activity and the scan area is sufficiently large to scan a
high number of tumor samples at the same time. How-
ever, the method depends on the presence of the phos-
phorous group at serine 473 in Akt that is responsible for
kinase activity. This modification has previously been
found labile and is lost over time from isolation of the
tumor tissue until fixation or freezing [29]. In the present
study, the tumor samples were immediately divided into
two parts: one-half was immediately snap-frozen in liquid
nitrogen, and the other was immediately fixed. In addition,
Figure 6 Phosphatidylinositol 3-kinase inhibition induces changes in glucose and choline metabolism. (A), (C) In basal-like xenografts,
treatment with phosphatidylinositol 3-kinase (PI3K) inhibitors increased the concentration of phosphocholine (PCho; both MK-2206 and BEZ235)
and glycerophosphocholine (GPC; BEZ235 only). BEZ235 caused an increase in the glucose concentration, whereas both MK-2206 and BEZ235
reduced the lactate concentration. (B), (D) No treatment-related changes in these metabolites were observed in luminal-like xenografts.
*Significantly different from control (P <0.05).
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the fixative was injected into the tumors to avoid depho-
sphorylation of Akt deeper inside the tumor tissue. In the
xenograft tissue, the use of anti-mouse secondary antibo-
dies gave rise to a significant signal in tissue with a high
content of murine stromal components. However, the fea-
sibility study performed in human BLBC specimens
demonstrated that both total Akt and pAktser473 levels
could be quantified with high specificity without contribu-
tion from unspecific binding of the secondary antibodies.
In the clinical setting, the method could be useful for
determining activity of Akt for stratification of patients to
treatment with PI3K inhibitors. The finding that pAktser473
is clearly elevated in only one in five cases of BLBC under-
scores the importance of subgrouping these patients.
Using conventional immunohistochemistry, Lopez-
Knowles and coworkers found an elevated level of pAkt-
ser473 in 24% of 258 invasive breast cancer cases [8]. Inter-
estingly, there is a clear correlation between increased
pAkt and loss of PTEN (but not with mutations in
PIK3CA) in human tumors and breast cancer cell lines
[8,24]. In vitro sensitivity for the small-molecule inhibitor
LY294002 has been shown to correlate with loss of PTEN
[24]. Our finding that the pAktser473-positive and PTEN-
negative basal-like xenograft is sensitive towards both
MK-2206 and BEZ235 is thus in line with previous in vitro
observations.
In this study, two different inhibitors of PI3K signaling
were evaluated. MK-2206 is an allosteric pan-Akt inhibi-
tor with broad preclinical anti-tumor activity [19].
BEZ235 is a dual PI3K/mTOR inhibitor, which also has
broad antiproliferative effects in a wide range of in vitro
and in vivo cancer models [20]. Both drugs are currently
in phase I/phase II clinical trials [30]. PIK3CA muta-
tions, loss of PTEN and increased pAkt levels occur fre-
quently in BLBC. PI3K inhibitors have therefore been
suggested as a potentially suitable class of drugs for
treatment of this patient group [8,17]. BLBC is strongly
associated with the triple-negative phenotype, and
because no molecularly targeted treatment options exist
for this patient group, PI3K inhibitors have been sug-
gested to be of particular benefit [17]. However, several
studies have failed to identify a correlation between
Figure 7 High-resolution magic angle spinning magnetic resonance spectroscopy demonstrates changes in glucose and choline
metabolism. Example spectra from basal-like xenografts illustrate changes in (A) glucose and (B) choline metabolites. BEZ235 treatment (blue
spectra) increased the glucose concentration compared with vehicle control (red spectra). A concomitant decrease in lactate concentration was
observed. Both glycerophosphocholine (GPC) and phosphocholine (PCho) concentrations were also increased after BEZ235 treatment.
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PIK3CA mutations and response to PI3K inhibition. The
importance of PTEN loss as a single predictive biomar-
ker for response is also debatable [31]. Owing to the
complex relationships that determine response to treat-
ment, identification of predictive biomarkers is difficult.
Functional biomarkers such as pAktser473, which more
directly is linked to signal transduction activity, may
therefore have higher predictive specificity. The current
lack of predictive biomarkers for response to PI3K inhi-
bitors calls for alternative stratification strategies. One
approach is to identify biomarkers that are associated
with changes in the cancer cells after initiation of ther-
apy. Since oncogenic signaling directly regulates key
metabolic pathways in cancer, identification of metabolic
biomarkers for response to therapy could represent a
promising alternative [32].
In this study, the effect of PI3K inhibitors was markedly
different in basal-like and luminal-like xenografts. In the
luminal-like xenografts, no treatment-related effects on
tumor volume, cellular proliferation or pAktser473 levels
were observed. This indicates that PI3K signaling is not
the driving force of tumor growth in this model, which is
in accordance with its estradiol addiction [21] and the
low baseline level of pAktser473. The lack of pharmacody-
namic response was reflected in the absence of metabolic
changes seen in the HR MAS MRS data. In contrast, the
basal-like xenograft had a high baseline activity in the
PI3K pathway and responded strongly to treatment with
both MK-2206 and BEZ235. A long-term delay in tumor
growth was observed compared with vehicle-treated con-
trols, concurrent with a reduction in mitotic activity.
Furthermore, the levels of pAktser473 were reduced to
very low levels after 3 days of treatment with the PI3K
inhibitors. This observation confirms that the drug
indeed hits the target in this model, with concurrent
effects on cellular proliferation and tumor metabolism.
Both the PHH3 assay and the immunofluorescence ima-
ging analysis suggested that BEZ235 had a stronger inhi-
bitory effect than MK-2206 in basal-like xenografts, with
a significant correlation between Aktser473 phosphoryla-
tion and mitotic activity. This differential pharmacody-
namic effect between the drugs was also reflected in the
metabolic profiles. MK-2206 caused increased PCho con-
centration and reduced lactate concentration. The mag-
nitude of change in these metabolite concentrations was
larger in BEZ235-treated xenografts. In addition, GPC
and glucose concentrations were significantly increased.
The HR MAS MRS data indicated that PCho, GPC, lac-
tate and glucose are potential metabolic biomarkers for
response to PI3K inhibitors. These findings are in accor-
dance with previous studies demonstrating that phospho-
lipid and glucose metabolism pathways contain potential
metabolic biomarkers for response to molecularly tar-
geted drugs [11,12].
An abnormally high rate of glucose uptake and utiliza-
tion is seen in most cancers. In contrast to normal cells,
cancer cells extract energy from glucose through glyco-
lysis rather than oxidative phosphorylation, even under
normoxic conditions [33]. The low ATP yield is com-
pensated by a high metabolic flux [34]. This way, cancer
cells can produce energy while conserving carbon for
production of proteins and nucleotides. The glycolytic
activity is governed by the cellular microenvironment,
but is also regulated by oncogenic signaling [35-37]. The
regulatory effect of PI3K signaling on glucose metabo-
lism is complex and multilayered, and includes both
Akt-mediated induction of glucose transport and hexo-
kinase activity as well as stimulation of glycolytic rate
and lactate production mediated by HIF-1 and Myc
[14,38]. Blockade of the PI3K/Akt/mTOR signaling axis
has been shown to reduce glycolytic rate and lactate
production in cancer in vitro [39,40]. The high sensitiv-
ity and spectral resolution achieved in our study allowed
determination of both glucose and lactate concentration
ex vivo, demonstrating that inhibition of PI3K signaling
both increased glucose concentration and reduced lac-
tate concentration. As the lactate concentration can be
measured using in vivo MRS, this biomarker is interest-
ing with respect to preclinical therapy monitoring [41].
In the clinical setting, it is difficult to measure the lac-
tate concentration in breast cancer due to the interfer-
ence from lipids in this tissue. Hyperpolarized 13C
pyruvate may therefore be the best approach for clinical
assessment of glucose metabolism using MRS [42].
The oncogenic signaling pathways that regulate glu-
cose metabolism have also been shown to regulate cho-
line metabolism [13,43]. In breast cancer, abnormally
high concentrations of choline metabolites are observed
both in vitro and in vivo [44]. High levels of PCho, GPC
and choline were initially associated with a high turn-
over of cell membrane components in rapidly proliferat-
ing cells. Later studies indicated that the abnormal
choline metabolism in fact is directly linked to malig-
nant transformation [45]. Although the mechanisms are
not fully elucidated, accumulating evidence indicates
that synthesis and hydrolysis of PtdCho generates mito-
genic messenger molecules such as diacylglycerol, phos-
phatidic acid, arachidonic acid metabolites and PCho
itself [46-49]. Abnormal expression of both choline
kinase and phospholipases has been associated with
development of cancer [44,50]. It is therefore not sur-
prising that interfering with this metabolic system is
considered a valuable therapeutic approach. As an
example, drugs inhibiting choline kinase have shown
promising anti-tumoral effects in preclinical models and
have now entered clinical trials [44,51,52]. However,
changes in choline metabolites in response to targeted
therapy are poorly understood [53].
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From in vitro studies, cancer aggressiveness has gener-
ally been assumed to be associated with high PCho con-
centration, and response to therapy assumed to be
reflected in decreased concentrations of this metabolite
[54,55]. However, it is increasingly recognized that GPC
may be a relevant biomarker both in breast cancer and
other cancers [26,56,57]. Response to targeted therapy
may also be associated with increased concentration of
PCho and/or GPC [40,58,59]. The use of choline metabo-
lites as metabolic biomarkers for therapy monitoring
therefore requires knowledge about both subtype-specific
metabolic profiles and the changes associated with var-
ious targeted treatments in each distinct subtype. Choline
metabolism may respond differentially to targeted treat-
ment in vitro and in vivo, and this aspect must also be
taken into account [60,61]. In this study, both PCho and
GPC increased in basal-like xenografts after blockade of
the PI3K signaling. Previous in vitro studies of PI3K inhi-
bitors in prostate cancer, colon cancer and breast cancer
cell lines have suggested a reduced PCho concentration
and an increased GPC concentration, whereas in vivo
studies in glioblastoma xenografts have suggested a
decrease in tCho [40,62,63]. However, we anticipate that
the metabolic changes depend on the oncogenic signaling
abnormalities seen in different cancer subtypes. The
basal-like xenograft model has previously been shown to
have a distinct metabolic phenotype, which also was
found in a corresponding cohort of human breast cancer
biopsies [26]. Our data demonstrate a relationship
between PI3K/Akt/mTOR signaling and choline metabo-
lism. As the basal-like xenograft is driven by PI3K signal-
ing, and as its distinct metabolic profile may be
associated with this signaling activity, the increased PCho
and GPC concentrations observed in this study might
possibly be unique features of the MAS98.12 basal-like
xenograft. Further studies in a larger panel of basal-like
xenografts, representing various genetic backgrounds and
metabolic profiles, are needed to elucidate these mechan-
isms and determine whether the metabolic effects are
representative for basal-like breast cancer in general.
From a clinical perspective, increased PCho and GPC
concentration translates into an increase in tCho, which
can be assessed in vivo using 1H MRS. Alternatively, in
vivo 31P spectroscopy could be a possible approach for
clinical applications, because this method allows spectral
resolution of the phosphomonoesters and diesters PCho,
phosphoethanolamine, GPC and glycerophosphoethano-
lamine in clinical magnetic resonance systems [64].
This study indicates that PI3K inhibitors may be of
value in treatment of basal-like breast cancer with high
pAkt levels and/or PTEN loss. Early metabolic changes
reflected the long-term inhibitory effect on tumor
growth. Several studies have suggested that PI3K inhibi-
tors must be combined with other targeted drugs or
classical chemotherapy in order to induce apoptosis or
kill the cancer cells, and this may also be the case in
basal-like breast cancer [65]. As choline metabolism
generally is more complex and variable than glucose
metabolism in terms of response to therapy, one could
assume that assessment of the glycolytic rate and down-
stream metabolites of glucose may be the most univer-
sally applicable approach for identifying relevant
metabolic biomarkers. On the contrary, choline metabo-
lism is richer in information and could potentially pro-
vide prognostic value in addition to use in therapy
monitoring. Finally, it is plausible that lack of a meta-
bolic response, or return to the pretreatment metabolic
profile, is associated with primary or acquired drug
resistance.
Conclusion
In summary, we have demonstrated that the PI3K signal-
ing inhibitors MK-2206 and BEZ235 inhibited prolifera-
tion and inhibited tumor growth in a basal-like xenograft
model. The response correlated to the inhibition of
Aktser473 phosphorylation. No response was seen in lumi-
nal-like xenografts, which had lower baseline activity in
the PI3K pathway. Using ex vivo HR MAS MRS, we
found that response to PI3K inhibition was associated
with reduced lactate concentration and increased con-
centration of PCho, GPC and glucose. The magnitude of
the metabolic response was reflected the inhibition of
cancer cell proliferation and the reduction in pAkt ser473
level. Since only a subset of patients with BLBC display a
clearly elevated pAktser473 signal, the sensitivity to PI3K
inhibitors may be variable. This heterogeneity under-
scores the need for functional biomarkers that can pre-
dict or detect response to treatment. Lactate, PCho and
GPC can potentially be imaged noninvasively in vivo
using MRS, and may therefore be valuable biomarkers
for early monitoring of response to PI3K inhibition in
basal-like breast cancer.
Additional material
Additional file 1: Table S1 presenting metabolite concentrations of
alanine, creatine, choline, phosphocholine, glycerophosphocholine,
taurine, glycine, glucose and lactate in basal-like and luminal-like
xenografts treated with vehicle, MK-2206 or BEZ235 (µmol/g, mean
± standard deviation). *Significantly different from vehicle-treated
controls.
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